Treats hypertension. ANDA 205823, held by Prinston. Quinapril Hydrochloride.
As of Nov 16, 2026, ANDA 205823 (Quinapril Hydrochloride), held by Prinston, was first approved by FDA on Sep 15, 2016, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Hypertension Quinapril tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2016 | Original application | Approved | None posted |
| Quinapril HydrochlorideEQ 5MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 10MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 20MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 40MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Nov 1, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 15, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters